Experienced in Microcephaly Deafness Syndrome

Dr. Priya S. Kishnani

Pediatrics
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Microcephaly Deafness Syndrome
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Priya Kishnani is a Pediatrics provider in Durham, North Carolina. Dr. Kishnani is rated as an Experienced provider by MediFind in the treatment of Microcephaly Deafness Syndrome. Her top areas of expertise are Pompe Disease, Glycogen Storage Disease Type 3, Hypophosphatasia (HPP), Glycogen Storage Disease Type 9, and Splenectomy. Dr. Kishnani is currently accepting new patients.

Her clinical research consists of co-authoring 339 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Microcephaly Deafness Syndrome.

Specialties
Pediatrics
Licenses
Pediatrics in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

GBE Deficiency (GSD IV and APBD) Natural History Study
GBE Deficiency (GSD IV and APBD) Natural History Study
Enrollment Status: Recruiting
Publish Date: May 28, 2025
Intervention Type: Other
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
Developing a Management Approach for Patients With Late-Onset Pompe Disease GAA Variant Identified by Newborn Screening
Developing a Management Approach for Patients With Late-Onset Pompe Disease GAA Variant Identified by Newborn Screening
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other
Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy
Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy
Enrollment Status: Terminated
Publish Date: September 19, 2024
The Down Syndrome Clinical Trials Network (DS-CTN) Study of Alzheimer's Disease in Down Syndrome
The Down Syndrome Clinical Trials Network (DS-CTN) Study of Alzheimer's Disease in Down Syndrome
Enrollment Status: Terminated
Publish Date: June 27, 2024
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
Enrollment Status: Completed
Publish Date: February 01, 2022
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 4
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Three-Month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Versus Myozyme®/Lumizyme® in Patients With Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment With VAL-1221 in All Patients
A Three-Month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Versus Myozyme®/Lumizyme® in Patients With Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment With VAL-1221 in All Patients
Enrollment Status: Terminated
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

337 Total Publications

Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2.
Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2.
Journal: Science advances
Published: November 12, 2025
Similar Doctors
Experienced in Microcephaly Deafness Syndrome
Dr. Ermal Aliu
Pediatrics | Medical Genetics
Experienced in Microcephaly Deafness Syndrome
Dr. Ermal Aliu
Pediatrics | Medical Genetics

Duke Health Integrated Practice Inc

4709 Creekstone Dr, Suite 300, 
Durham, NC 
 (9.9 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances

Ermal Aliu is a Pediatrics specialist and a Medical Genetics provider in Durham, North Carolina. Dr. Aliu is rated as an Advanced provider by MediFind in the treatment of Microcephaly Deafness Syndrome. His top areas of expertise are Phenylketonuria (PKU), Learman Syndrome, Microcephaly, and Symphalangism Distal.

Experienced in Microcephaly Deafness Syndrome
Dr. Vandana S. Shashi
Medical Genetics | Pediatrics
Experienced in Microcephaly Deafness Syndrome
Dr. Vandana S. Shashi
Medical Genetics | Pediatrics

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Vandana Shashi is a Medical Genetics specialist and a Pediatrics provider in Durham, North Carolina. Dr. Shashi is rated as a Distinguished provider by MediFind in the treatment of Microcephaly Deafness Syndrome. Her top areas of expertise are DiGeorge Syndrome, Hypotonia, Immune Defect due to Absence of Thymus, and Micrognathia. Dr. Shashi is currently accepting new patients.

Experienced in Microcephaly Deafness Syndrome
Dr. Suzanne S. Covington
Pediatrics
Experienced in Microcephaly Deafness Syndrome
Dr. Suzanne S. Covington
Pediatrics
2406 Blue Ridge Rd Ste 100, 
Raleigh, NC 
 (17.9 miles away)
919-786-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzanne Covington is a Pediatrics provider in Raleigh, North Carolina. Dr. Covington is rated as an Advanced provider by MediFind in the treatment of Microcephaly Deafness Syndrome. Her top areas of expertise are Obesity in Children, Croup, Herpangina, and Delayed Growth. Dr. Covington is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kishnani's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile